Down syndrome's protection against neuroblastoma: The stromal and neural overmaturation tracks

Neuroblastoma Research Trends

Volumn , Issue , 2008, Pages 57-100

  Satgé, Daniel ^a   Créau, Nicole ^b   Aflalo Rattenbach, Revital ^b   Ducassou, Stéphane ^c   Lutz, Patrick ^c   Bénard, Jean ^d  

^a CENTRE HOSPITALIER   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c HÔPITAL DE HAUTEPIERRE   (France)

^d INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 79960852855     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (174)

1. Abe M, Sato Y. cDNA microarray analysis of the gene expression profile of VEGF-activated human umbilical vein endothelial cells. Angiogenesis 2001;4:289-98
2. Airoldi I, Meazza R, Croce M, Di Carlo E, Piazza T, Cocco C, D'Antuono T, Pistoia V, Ferrini S, Corrias MV. Low-dose interferon-gamma-producing human neuroblastoma cells show reduced proliferation and delayed tumorigenicity. Br. J. Cancer 2004; 90:2210-8
3. Al-Hermi BE, Thorner PS, Arbus GS. Acute plasmacytic interstitial nephritis in a child with Down syndrome. Pediatr. Nephrol. 1999;13:333-5
4. Allinquant B, Hantraye P, Mailleux P, Moya K, Bouillot C, Prochiantz A. Downregulation of amyloid precursor protein inhibits neurite outgrowth in vitro. J. Cell Biol. 1995;128:919-27
5. Allore RJ, Friend WC, O'Hanlon D, Neilson KM, Baumal R, Dunn RJ, Marks A. Cloning and expression of the human S100 beta gene. J. Biol. Chem. 1990;265:15537-43
6. Ando K, Oishi M, Takeda S, Iijima K, Isohara T, Nairn AC, Kirino Y, Greengard P, Suzuki T. Role of phosphorylation of Alzheimer's amyloid precursor protein during neuronal differentiation. J. Neurosci. 1999;19:4421-7
7. Barger GR, Douglas JG Kupski WJ, Sloan AE, Zak IT. Medulloblastoma. In: Berger MS and Prados MD (Eds). Textbook of Neuro-Oncology. Philadelphia: Elsevier Saunders; 2005;pp253-4
8. Barlow GM, Lyons GE, Richardson JA, Sarnat HB, Korenberg JR. DSCAM: an endogenous promoter drives expression in the developing CNS and neural crest. Biochem. Biophys. Res. Commun. 2002; 299:1
9. Becker L, Mito T, Takashima S, Onodera K. Growth and development of the brain in Down syndrome. Prog. Clin. Biol. Res.1991;373:133-152
10. Bénard J, Beron-Gaillard N, Satge D. Down's syndrome protects against breast cancer: is a constitutional cell microenvironment the key? Int. J. Cancer 2005;113:168-70
11. Benda CE. Endocrine aspects of mongolism. J. Clin. Endocrinol. 1942;2:737-48
12. Benda CE. The suprarenal glands. In: Benda CE (Ed). The child with mongolism. New York: Grune and Stratton; 1960; pp131-9
13. Bhowmick NA, Neilson EG, Moses HL. Stromal fibroblasts in cancer initiation and progression. Nature 2004;432:332-7
14. Biedler JL. Helson L, Spengler BA. Morphology and growth, tumorigenicity, and cytogenetics of human neuroblastoma cells in continuous culture. Cancer Res. 1973; 33: 2643-52
15. Biedler JL, Spengler BA. A novel chromosome abnormality in human neuroblastoma and antifolate-resistant chinese hamster cell lines in culture. J. Natl. Cancer Inst. 1976; 57: 683-9
16. Boker LK, Merrick J. Cancer incidence in persons with Down syndrome in Israel. Downs Syndr. Res. Pract. 2002;8:31-6
17. Borodinsky LN, Coso OA, Fiszman ML. Contribution of Ca2+ calmodulindependent protein kinase II and mitogen-activated protein kinase kinase to neural activity-induced neurite outgrowth and survival of cerebellar granule cells. J. Neurochem. 2002; 80:1062-70
18. Breen KC, Bruce M, Anderton BH. Beta amyloid precursor protein mediates neuronal cell-cell and cell-surface adhesion. J. Neurosci. Res. 1991;28:90100
19. Brooksbank BW, Walker D, Balazs R, Jorgensen OS. Neuronal maturation in the foetal brain in Down's syndrome. Early Hum. Dev. 1989;18:237-46
20. Busciglio J, Yankner BA. Apoptosis and increased generation of reactive oxygen species in Down's syndrome neurons in vitro. Nature 1995;378:776-9
21. Buxhoeveden D, Fobbs A, Roy E, Casanova M. Quantitative comparison of radial cell columns in children with Down's syndrome and controls. J. Intellect. Disabil. Res. 2002; 46: 76-81
22. Buxhoeveden D, Casanova MF. Accelerated maturation in brains of patients with Down syndrome. J. Intellect. Disabil. Res. 2004;48:704-5
23. Cabin DE, Gardiner K, Reeves RH. Molecular genetic characterization and comparative mapping of the human PCP4 gene. Somat. Cell Mol. Genet. 1996;22:167-75
24. Casanova MF, Walker LC, Whitehouse PJ, Price DL. Abnormalities of the nucleus basalis in Down's syndrome. Ann. Neurol. 1985;18:310-3
25. Ceballos-Picot I, Nicole A, Briand P, Grimber G, Delacourte A, Defossez A, Javoy-Agid F, Lafon M, Blouin JL, Sinet PM. Neuronal-specific expression of human copper-zinc superoxide dismutase gene in transgenic mice: animal model of gene dosage effects in Down's syndrome. Brain Res. 1991; 552:198214
26. Chen SL, Orr HT. Sequence of a murine cDNA, pcp-4, that encodes the homolog of the rat brain-specific antigen PEP-19. Nucleic Acids Res. 1990; 18:1304
27. Cohen WI. Health car guidelines for individuals with Down syndrome. Down Syndrome Quaterly 1999; 4:1-16
28. Cools M, Honecker F, Stoop H, Veltman JD, de Krijger RR, Steyerberg E, Wolffenbuttel KP, Bokemeyer C, Lau YF, Drop SL, Looijenga LH. Maturation delay of germ cells in fetuses with trisomy 21 results in increased risk for the development of testicular germ cell tumors. Hum. Pathol. 2006;37:101-11
29. Cooper MJ, Hutchins GM, Israel MA. Histogenesis of the human adrenal medulla. An evaluation of the ontogeny of chromaffin and nonchromaffin lineages. Am. J. Pathol. 1990; 137:605-15
30. Cornaglia-Ferraris P, Mariottini GL, Ponzoni M. Gamma-interferon and retinoic acid synergize in inhibiting the growth of human neuroblastoma cells in nude mice. Cancer Lett. 1992;61:215-20
31. de Haan JB, Cristiano F, Iannello R, Bladier C, Kelner MJ, Kola I. Elevation in the ratio of Cu/Zn-superoxide dismutase to glutathione peroxidase activity induces features of cellular senescence and this effect is mediated by hydrogen peroxide. Hum. Mol. Genet. 1996; 5: 283-92
32. Delfini C. Contributo allo studio del mongolismo. Rev Speriment Pediatr. Med. Legale. 1932; 56:162-217
33. De Wever O, Mareel M. Role of tissue stroma in cancer cell invasion. J. Pathol. 2003; 200: 429-47
34. Dickerson JB, Morgan MA, Mishra A, Slaughter CA, Morgan JI, Zheng J. The influence of phosphorylation on the activity and structure of the neuronal IQ motif protein, PEP-19. Brain Res. 2006; 1092:16-27
35. Dieckmann KP, Rube C, Henke RP. Association of Down's syndrome and testicular cancer. J. Urol. 1997;157:1701-4
36. Dixon N, Kishnani PS, Zimmerman S. Clinical manifestations of hematologic and oncologic disorders in patients with Down syndrome. Am. J. Med. Genet. C Semin. Med. Genet. 2006; 142:149-57
37. Donato R. Functional roles of S100 proteins, calcium-binding proteins of the EF-hand type. Biochim. Biophys. Acta. 1999; 1450:191-231
38. Donato R. Intracellular and extracellular roles of S100 proteins. Microsc. Res. Tech. 2003; 60:540-51
39. Eberhard Y, Eterradossi J, Therminarias A. Biochemical changes and catecholamine responses in Down's syndrome adolescents in relation to incremental maximal exercise. J. Ment. Defic. Res. 1991;35: 140-6
40. Edsjo A, Holmquist L, Pahlman S. Neuroblastoma as an experimental model for neuronal differentiation and hypoxia-induced tumor cell dedifferentiation. Semin. Cancer Biol. 2006 (in press)
41. El-Ghissassi F, Valsesia-Wittmann S, Falette N, Duriez C, Walden PD, Puisieux A. BTG2(TIS21/PC3) induces neuronal differentiation and prevents apoptosis of terminally differentiated PC12 cells. Oncogene 2002;21:6772-78
42. Encinas M, Iglesias M, Liu Y, Wang H, Muhaisen A, Cena V, Gallego C, Comella JX. Sequential treatment of SH-SY5Y cells with retinoic acid and brain-derived neurotrophic factor gives rise to fully differentiated, neurotrophic factor-dependent, human neuron-like cells. J. Neurochem. 2000; 75:991-1003
43. Epstein CJ. Specificity versus nonspecificity in the pathogenesis of aneuploid phenotypes. Am. J. Med. Genet. 1988; 29:161-5
44. Epstein CJ. The consequences of chromosome imbalance. Am. J. Med. Genet. Suppl. 1990; 7: 31-7
45. Epstein CJ. Down syndrome (trisomy 21). In: Scriver CR, Beaudet AL, Sly WS, Valle D. (Eds). The metabolic and molecular bases of inherited diseases. New York: McGraw-hill; 2001;pp1223-57
46. Erhardt JA, Legos JJ, Johanson RA, Slemmon JR, Wang X. Expression of PEP19 inhibits apoptosis in PC12 cells. Neuroreport 2000;11:3719-23
47. Fabia J, Drolette M. Malformations and leukemia in children with Down's syndrome. Pediatrics 1970;45:60-70
48. Fano G, Mariggio MA, Angelella P, Nicoletti I, Antonica A, Fulle S, Calissano P. The S-100 protein causes an increase of intracellular calcium and death of PC12 cells. Neuroscience 1993; 53:919-25
49. Feingold M, Gheradi GJ, Simons C. Familial neuroblastoma and trisomy 13. Am. J. Dis. Child 1971;121:451
50. Fernhall B, Otterstetter M. Attenuated responses to sympathoexcitation in individuals with Down syndrome. J. Appl. Physiol. 2003;94:2158-65
51. Ferrandis E, Da Silva J, Riou G, Benard I. Coactivation of the MDR1 and MYCN genes in human neuroblastoma cells during the metastatic process in the nude mouse. Cancer Res. 1994; 54:2256-61
52. Fitzpatrick DR. Transcriptional consequences of autosomal trisomy: primary gene dosage with complex downstream effects. Trends Genet. 2005; 21: 249-53
53. Foos G, Garcia-Ramirez JJ, Galang CK, Hauser CA. Elevated expression of Ets2 or distinct portions of Ets2 can reverse Ras-mediated cellular transformation. J. Biol. Chem. 1998; 273: 18871-80
54. Foulkes WD, Buu PN, Filiatrault D, Leclerc JM, Narod SA. Excess of congenital abnormalities in French-Canadian children with neuroblastoma: a case series study from Montreal. Med. Pediatr. Oncol. 1997;29:272-9
55. Fuentes JJ, Genesca L, Kingsbury TJ, Cunningham KW, Perez-Riba M, Estivill X, de la Luna S. DSCR1, overexpressed in Down syndrome, is an inhibitor of calcineurin-mediated signaling pathways. Hum. Mol. Genet. 2000;9:1681-90
56. Gandolfi A, Horoupian DS, De Teresa RM. Pathology of the auditory system in autosomal trisomies with morphometric and quantitative study of the ventral cochlear nucleus. J. Neurol. Sci. 1981;51:43-50
57. Gardiner K. Predicting pathway perturbations in Down syndrome. J. Neural. Transm. Suppl. 2003; 67:21-37
58. Gardiner K, Davisson MT, Pritchard M, Patterson D, Groner Y, Crnic LS, Antonarakis S, Mobley W. Report on the ' Expert Workshop on the Biology of Chromosome 21: towards gene-phenotype correlations in Down syndrome',held June 11-14, 2004, Washington D.C. Cytogenet. Genome Res. 2005;108:269-77
59. Geraci AP, de Csepel J, Shlasko E, Wallace SA. Ganglioneuroblastoma and ganglioneuroma in association with neurofibromatosis type I: report of three cases. J. Child Neurol. 1998; 13: 356-8
60. Gerendasy D. Homeostatic tuning of Ca2+ signal transduction by members of the calpacitin protein family. J. Neurosci. Res. 1999;58:107-19
61. Gold DA, Baek SH, Schork NJ, Rose DW, Larsen DD, Sachs BD, Rosenfeld MG, Hamilton BA RORalpha coordinates reciprocal signaling in cerebellar development through sonic hedgehog and calcium-dependent pathways. Neuron 2003;40:1119-31
62. Gordon MB. Morphological changes in the endocrine glands in Mongolian idiocy with report of two cases. Endocrinology 1930;14:1-6
63. Hachitanda Y, Nakagawara A, Nagoshi M, Tsuneyoshi M. Prognostic value of Nmyc oncogene amplification and S-100 protein positivity in children with neuroblastic tumors. Acta Pathol. Jpn. 1992;42:639-44
64. Harimaya K, Oda Y, Matsuda S, Tanaka K, Chuman H, Iwamoto Y. Primitive neuroectodermal tumor and extraskeletal Ewing sarcoma arising primarily around the spinal column: report of four cases and a review of the literature. Spine 2003;28:E408-12
65. Hasle H, Clemmensen IH, Mikkelsen M. Risks of leukaemia and solid tumours in individuals with Down's syndrome. Lancet 2000;355:165-9
66. Hattori M, Fujiyama A, Taylor TD, Watanabe H, Yada T, Park HS, Toyoda A, Ishii K, Totoki Y, Choi DK, Groner Y, Soeda E, Ohki M, Takagi T, Sakaki Y, Taudien S, Blechschmidt K, Polley A, Menzel U, Delabar J, Kumpf K, Lehmann R, Patterson D, Reichwald K, Rump A, Schillhabel M, Schudy A, Zimmermann W, Rosenthal A, Kudoh J, Schibuya K, Kawasaki K, Asakawa S, Shintani A, Sasaki T, Nagamine K, Mitsuyama S, Antonarakis SE, Minoshima S, Shimizu N, Nordsiek G, Hornischer K, Brant P, Scharfe M, Schon O, Desario A, Reichelt J, Kauer G, Blocker H, Ramser J, Beck A, Klages S, Hennig S, Riesselmann L, Dagand E, Haaf T, Wehrmeyer S, Borzym K, Gardiner K, Nizetic D, Francis F, Lehrach H, Reinhardt R, Yaspo ML; Chromosome 21 mapping and sequencing consortium. The DNA sequence of human chromosome 21. Nature 2000;405:311-9
67. Hosoi H, Sawada T, Nakajima T, Kuroda H, Saida T, Sugimoto T, Tokiwa K, Ogita S. A case of mosaic Down's syndrome concomitant with ganglioneuroma. J. Pediatr. Surg. 1989; 24:210-1
68. Hu J, Ferreira A, van Eldik LJ. S100β induces neuronal cell death through nitric oxide release from astrocytes. J. Neurochem. 1997;69:2294-301
69. Huttunen HJ, Kuja-Panula J, Sorci G, Agneletti AL, Donato R, Rauvala H. Coregulation of neurite outgrowth and cell survival by amphoterin and S100 proteins through receptor for advanced glycation end products (RAGE) activation. J. Biol. Chem. 2000;275:40096-105
70. Isaacs H Jr. Neuroblastoma in situ. In: Isaacs H Jr (Ed). Tumors of the fetus and newborn. Philadelphia: WB Saunders; 1997;p145
71. Israel MA. Disordered differentiation as a target for novel approaches to the treatment of neuroblastoma. Cancer 1993;71:3310-3
72. Iwanaga T, Fujita T. Sustentacular cells in the fetal human adrenal medulla are immunoreactive with antibodies to brain S-100 protein. Cell Tissue Res. 1984;236:733-5
73. Johanson RA, Sarau HM, Foley JJ, Slemmon JR. Calmodulin-binding peptide PEP-19 modulates activation of calmodulin kinase II In situ. J. Neurosci. 2000;20:2860-6
74. Joshi VV, Balarezo F, Hicks MJ, Mierau GW, Tsongalis GJ. Approach to small round cell tumors of childhood. Pathology case Reviews 2000;5:26-41
75. Kenny PA, Bissell MJ. Tumor reversion: correction of malignant behavior by microenvironmental cues. Int. J. Cancer 2003;107:688-95
76. Kissane JM. Introdution, Embryonal tumors. Semin. Diagn. Pathol. 1994;11:83-4
77. Kligman D, Hsieh LS. Neurite extension factor induces rapid morphological differentiation of mouse neuroblastoma cells in defined medium. Dev. Brain Res. 1987;33:296-300
78. Komatsu T, Kubota E, Sakai N. Enhancement of matrix metalloproteinase (MMP)-2 activity in gingival tissue and cultured fibroblasts from Down's syndrome patients. Oral Dis. 2001; 7:47-55
79. Korenberg JR, Chen XN, Schipper R, Sun Z, Gonsky R, Gerwehr S, Carpenter N, Daumer C, Dignan P, Disteche C, et al. Down syndrome phenotypes: the consequences of chromosomal imbalance. Proc. Natl. Acad. Sci. USA. 1994;91:4997-5001
80. Koyama T, Kanadani T, Tanaka M, Nakahara S, Yamadori I. A case of Down's syndrome associated with progressive extradural neuroblastoma. Pediatr. Surg. Int. 1999;15:373-5
81. Kramer S, Ward E, Meadows AT, Malone KE. Medical and drug risk factors associated with neuroblastoma: a case-control study. J. Natl. Cancer Inst. 1987;78:797-804
82. Kreiner E. Weight and shape of the human adrenal medulla in various age groups. Virchows Arch. A Pathol. Anat. Histol. 1982;397:7-15
83. Kuroiwa M, Takeuchi T, Lee JH, Yoshizawa J, Hirato J, Kaneko S, Choi SH, Suzuki N, Ikeda H, Tsuchida Y. Continuous versus intermittent administration of human endostatin in xenografted human neuroblastoma. J. Pediatr. Surg. 2003;38:1499-505
84. Kwiatkowski JL, Rutkowski JL, Yamashiro DJ, Tennekoon GI, Brodeur GM. Schwann cell-conditioned medium promotes neuroblastoma survival and differentiation. Cancer Res. 1998; 58:4602-6
85. Lake CR, Ziegler MG, Coleman M, Kopin IJ. Evaluation of the sympathetic nervous system in trisomy-21 (Down's syndrome). J. Psychiatr. Res. 1979;15(1):1-6
86. Lange P. Beitrag zur patologischen Anatomie des Mongolismus. Monatsschr. Kinderheilkd. 1906; 5:233-43
87. Lejeune J, Gautier M, Turpin R. Study of somatic chromosomes from 9 mongoloid children. C R Acad. Sci. 1959;248:1721-2
88. Lhermitte J. Sloboziano H., Radovici A. Contribution à l'étude anatomique de l'idiotie mongolienne. Bull. Soc. Pediat. Paris. 1921;19:187-96
89. Luthi-Carter R, Hanson SA, Strand AD, Bergstrom DA, Chun W, Peters NL, Woods AM, Chan EY, Kooperberg C, Krainc D, Young AB, Tapscott SJ, Olson JM. Dysregulation of gene expression in the R6/2 model of polyglutamine disease: parallel changes in muscle and brain. Hum. Mol. Genet. 2002;11:1911-26
90. Ma'ayan A, Gardiner K, Iyengar R. The cognitive phenotype of Down syndrome: insights from intracellular network analysis. NeuroRx. 2006;3:396-406
91. Magro G, Grasso S. Immunohistochemical identification and comparison of glial cell lineage in foetal, neonatal, adult and neoplastic human adrenal medulla. Histochem. J. 1997; 29: 293-9
92. Marcus K, Johnson M, Adam RM, O'Reilly MS, Donovan M, Atala A, Freeman MR, Soker S. Tumor cell-associated neuropilin-1 and vascular endothelial growth factor expression as determinants of tumor growth in neuroblastoma. Neuropathology 2005;25:178-87
93. Marenholz I, Heizmann CW, Fritz G. S100 proteins in mouse and man: from evolution to function and pathology (including an update of the nomenclature). Biochem. Biophys. Res. Commun. 2004; 322: 1111-22
94. Maris JM, Kyemba SM, Rebbeck TR, White PS, Sulman EP, Jensen SJ, Allen C, Biegel JA, Brodeur GM. Molecular genetic analysis of familial neuroblastoma. Eur. J. Cancer 1997; 33:1923-8
95. McSwigan JD, Hanson DR, Lubiniecki A, Heston LL, Sheppard JR. Down syndrome fibroblasts are hyperresponsive to beta-adrenergic stimulation. Proc. Natl. Acad. Sci. USA 1981;78:7670-3
96. McWilliams N.B. Neuroblastoma in infancy. In: Neuroblastoma: tumor biology and therapy. Pocheldy C (Ed). Boca Raton: CRC Press; 1990;pp 229-43
97. Michaelis M, Suhan T, Cinatl J, Driever PH, Cinatl J Jr. Valproic acid and interferon-alpha synergistically inhibit neuroblastoma cell growth in vitro and in vivo. Int. J. Oncol. 2004; 25:1795-9
98. Michetti F, Larocca LM, Rinelli A, Lauriola L. Immunocytochemical distribution of S-100 protein in patients with Down's syndrome. Acta Neuropathol. 1990; 80:475-8.
99. Miller RW, Fraumeni JF Jr, Hill JA. Neuroblastoma: epidemiologic approach to its origin. Am. J. Dis. Child 1968;115:253-61
100. Miller RW. Childhood cancer and congenital defects. A study of U.S. death certificates during the period 1960-1966. Pediatr. Res. 1969;3:389-97
101. Minami T, Horiuchi K, Miura M, Abid MR, Takabe W, Noguchi N, Kohro T, Ge X, Aburatani H, Hamakubo T, Kodama T, Aird WC. Vascular endothelial growth factor-and thrombin-induced termination factor, Down syndrome critical region-1, attenuates endothelial cell proliferation and angiogenesis. J. Biol. Chem. 2004;279:50537-54
102. Misugi K, Aoki I, Kikyo S, Sasaki Y, Tsunoda A, Nakajima T. Immunohistochemical study of neuroblastoma and related tumors with anti-S100 protein antibody. Pediatr. Pathol. 1985; 3:217-26
103. Mito T, Becker LE. Developmental changes of S-100 protein and glial fibrillary acidic protein in the brain in Down syndrome. Exp. Neurol. 1993;120:170-6
104. Moore BW. A soluble protein characteristic of the nervous system. Biochem. Biophys. Res. Commun.1965; 19:739-44
105. Mora J, Gerald WL. Origin of neuroblastic tumors: clues for future therapeutics. Expert Rev. Mol. Diagn. 2004;4:293-302
106. Nagoshi M, Tsuneyoshi M, Enjoji M. S-100 positive undifferentiated neuroblastomas with a special reference to the tumor stroma related to favorable prognosis. Pathol. Res. Pract. 1992; 188:273-83
107. Nakazato Y, Landing BH. Reduced number of neurons in esophageal plexus ganglia in Down syndrome: additional evidence for reduced cell number as a basic feature of the disorder. Pediatr. Pathol. 1986;5:55-63
108. Narod SA, Stiller C, Lenoir GM. An estimate of the heritable fraction of childhood cancer. Br. J. Cancer 1991;63:993-9
109. Neglia JP, Smithson WA, Gunderson P, King FL, Singher LJ, Robison LL. Prenatal and perinatal risk factors for neuroblastoma. A case-control study. Cancer 1988;61:2202-6
110. Nevin NC, Dodge JA, Allen IV. Two cases of trisomy D associated with adrenal tumours. J. Med. Genet. 1972;9:119-22
111. Nishi M, Miyake H, Takeda T, Hatae Y. Congenital malformations and childhood cancer. Med. Pediatr. Oncol. 2000;34:250-4
112. Nishiyama H, Knopfel T, Endo S, Itohara S. Glial protein S100B modulates long-term neuronal synaptic plasticity. Proc. Natl. Acad. Sci. USA. 2002;99:403742
113. Olshan AF, Bunin GR. Epidemiology of neuroblastoma. In: Brodeur GM, Sawada T, Tsuchida Y, Voute PA, (Eds). Neuroblastoma. Amsterdam. Elsevier; 2000;pp33-9
114. Patja K, Pukkala E, Sund R, Iivanainen M, Kaski M. Cancer incidence of persons with Down syndrome in Finland: a population-based study. Int. J. Cancer 2006; 118:1769-72
115. Pearson ADJ, Pinkerton R. Neuroblastoma. In: Pinkerton R, Plowman PN, Pieters R, (Eds). Pediatric Oncology 3rd edition. London: Arnold; 2004;pp386-7
116. Pennacchietti M. Contributo anatomo-patologico allo studio della idioza mongoloide. Endocrinologia Patologia 1935; 10:148-64
117. Pearlson GD, Breiter SN, Aylward EH, Warren AC, Grygorcewicz M, Frangou S, Barta PE, Pulsifer MB. MRI brain changes in subjects with Down syndrome with and without dementia. Dev. Med. Child Neurol. 1998;40:326-34
118. Pine SS, Landing BH, Shankle WR. Reduced inferior olivary neuron number in early Down syndrome. Pediatr. Pathol. Lab. Med. 1997;17:537-45
119. Plioplys AV. Down's syndrome. Precocious neurofilament antigen expression. J. Neurol. Sci. 1987; 79:91-100
120. Przyborski SA, Smith S, Wood A. Transcriptional profiling of neuronal differentiation by human embryonal carcinoma stem cells in vitro. Stem Cells 2003; 21:459-71
121. Putkey JA, Kleerekoper Q, Gaertner TR, Waxham MN. A new role for IQ motif proteins in regulating calmodulin function. J. Biol. Chem. 2003; 278: 4966770
122. Qiu WQ, Ferreira A, Miller C, Koo EH, Selkoe DJ. Cell-surface beta-amyloid precursor protein stimulates neurite outgrowth of hippocampal neurons in an isoform-dependent manner. J. Neurosci. 1995; 15:2157-67
123. Raio L, Cromi A, Ghezzi F, Passi A, Karousou E, Viola M, Vigetti D, De Luca G, Bolis P. Hyaluronan content of Wharton's jelly in healthy and Down syndrome fetuses. Matrix Biol. 2005;24:166-74
124. Ribatti D, Nico B, Pezzolo A, Vacca A, Meazza R, Cinti R, Carlini B, Parodi F, Pistoia V, Corrias MV. Angiogenesis in a human neuroblastoma xenograft model: mechanisms and inhibition by tumour-derived interferon-gamma. Br. J. Cancer 2006;94:1845-52
125. Rickert CH, Gocke H, Paulus W. Fetal ependymoma associated with Down's syndrome. Acta Neuropathol. 2002;103:78-81
126. Ridge J, Terle DA, Dragunsky E, Levenbook I. Effects of gamma-IFN and NGF on subpopulations in a human neuroblastoma cell line: flow cytometric and morphological analysis. In Vitro Cell Dev. Biol. Anim. 1996;32:238-48
127. Robinson MG, McCorquodale MM. Trisomy 18 and neurogenic neoplasia. J. Pediatr. 1981; 99:428-9
128. Rohrer T, Trachsel D, Engelcke G, Hammer J. Congenital central hypoventilation syndrome associated with Hirschsprung's disease and neuroblastoma: case of multiple neurocristopathies. Pediatr Pulmonol. 2002;33:71-6
129. Roper RJ, Reeves RH. Understanding the basis for Down syndrome phenotypes. PLoS Genet. 2006;2:e50
130. Russell BG, Kjaer I. Tooth agenesis in Down syndrome. Am J Med Genet. 1995;55:466-71
131. Sangameswaran L, Hempstead J, Morgan JI. Molecular cloning of a neuron-specific transcript and its regulation during normal and aberrant cerebellar development. Proc. Natl. Acad. Sci. USA. 1989;86:5651-5
132. Sasco AJ, Gendre I, Verbier-Naneix C, Soulier J-L, Raffi F, Satgé D, Robert E. Neonatal neuroblastoma in utero exposure to progestagens. Int. J. Risk Safety Med. 1998; 11:121-8
133. Satgé D.A decreased incidence of neuroblastomas in Down's syndrome and overproduction of S-100 b protein. Med. Hypotheses 1996;46:393-9
134. Satgé D, Van den Berghe H. Aspects of the neoplasms observed in patients with constitutional autosomal trisomy. Cancer Genet. Cytogenet. 1996;87:63-70
135. Satgé D, Sasco AJ, Cure H, Leduc B, Sommelet D, Vekemans MJ. An excess of testicular germ cell tumors in Down's syndrome: three case reports and a review of the literature. Cancer 1997;80:929-35
136. Satgé D, Sommelet D, Geneix A, Nishi M, Malet P, Vekemans M. A tumor profile in Down syndrome. Am. J. Med. Genet. 1998a;78:207-16
137. Satgé D, Sasco AJ, Carlsen NL, Stiller CA, Rubie H, Hero B, de Bernardi B, de Kraker J, Coze C, Kogner P, Langmark F, Hakvoort-Cammel FG, Beck D, von der Weid N, Parkes S, Hartmann O, Lippens RJ, Kamps WA, Sommelet D. A lack of neuroblastoma in Down syndrome: a study from 11 European countries. Cancer Res. 1998b; 58:448-52
138. Satgé D, Rubie H, Sommelet D. Paravertebral neoplasm in a child with Down syndrome (DS). Pediatr. Surg. Int. 2001a;17:251
139. Satgé D, Monteil P, Sasco AJ, Vital A, Ohgaki H, Geneix A, Malet P, Vekemans M, Rethore MO. Aspects of intracranial and spinal tumors in patients with Down syndrome and report of a rapidly progressing Grade 2 astrocytoma. Cancer 2001b;91:1458-66
140. Satgé D, Moore SW, Stiller CA, Niggli FK, Pritchard-Jones K, Bown N, Benard J, Plantaz D. Abnormal constitutional karyotypes in patients with neuroblastoma: a report of four new cases and review of 47 others in the literature. Cancer Genet. Cytogenet. 2003a;147:89-98
141. Satgé D, Sasco AJ, Chompret A, Orbach D, Mechinaud F, Lacour B, Roullet B, Martelli H, Bergeron C, Bertrand Y, Lacombe D, Perel Y, Monteil P, Nelken B, Bertozzi AI, Munzer M, Kanold J, Bernard F, Vekemans MJ, Sommelet D. A 22-year French experience with solid tumors in children with Down syndrome. Pediatr. Hematol. Oncol. 2003b;20:517-29
142. Schneid H, Vazquez MP, Vacher C, Gourmelen M, Cabrol S, Le Bouc Y. The Beckwith-Wiedemann syndrome phenotype and the risk of cancer. Med. Pediatr. Oncol. 1997; 28: 411-5
143. Selinfreund RH, Barger SW, Pledger WJ, van Eldik LJ. Neurotrophic protein S100ßß stimulates glial cell proliferation. Proc. Natl. Acad. Sci. USA 1991; 88:3554-8
144. Shaked GM, Kummer MP, Lu DC, Galvan V, Bredesen DE, Koo EH. Abeta induces cell death by direct interaction with its cognate extracellular domain on APP (App 597-624). FASEB J. 2006;20:1254-6
145. Shanklin DR, Sotelo-Avila C. In situ tumors in fetuses, newborns and young infants. Biol. Neonat. 1969;14:286-316
146. Shehata BM, Abramowsky CR. Alveolar capillary dysplasia in an infant with trisomy 21. Pediatr. Dev. Pathol. 2005;8:696-700
147. Sheppard JR, Schumacher W, White JG, Jakobs KH, Schultz G. The alpha adrenergic response of Down's syndrome platelets. J. Pharmacol. Exp. Ther. 1983; 225:584-8
148. Shimada H, Aoyama C, Chiba T, Newton WA. Prognostic subgroups for undifferentiated neuroblastoma. Hum. Pathol. 1985;16:471-6
149. Shojaei-Brosseau T, Chompret A, Abel A, de Vathaire F, Raquin MA, Brugieres L, Feunteun J, Hartmann O, Bonaiti-Pellie C. Genetic epidemiology of neuroblastoma: a study of 426 cases at the Institut Gustave-Roussy in France. Pediatr. Blood Cancer 2004;42:99-105
150. Skog J, Mei YF, Wadell G. Human adenovirus serotypes 4p and 11p are efficiently expressed in cell lines of neural tumour origin. J. Gen. Virol. 2002;83:1299-309
151. Slemmon JR, Morgan JI, Fullerton SM, Danho W, Hilbush BS, Wengenack TM. Camstatins are peptide antagonists of calmodulin based upon a conserved structural motif in PEP-19, neurogranin, and neuromodulin. J. Biol. Chem. 1996;271:15911-7
152. Spiryda LB, Colman DR. Suppression of tumorigenicity in an aggressive cervical carcinoma induced by protein zero, a nervous system IgCAM. J. Cell Sci. 1998;111:3253-60
153. Stiller CA. Aetiology and epidemiology. In: Pinkerton R, Plowman PN, Pieters R, (Eds). Pediatric Oncology 3rd edition. London: Arnold; 2004;pp3-18
154. Streck CJ, Zhang Y, Miyamoto R, Zhou J, Ng CY, Nathwani AC, Davidoff AM. Restriction of neuroblastoma angiogenesis and growth by interferonalpha/beta. Surgery 2004;136: 183-9
155. Sy WM, Edmonson JH. The development defects associated with neuroblastoma-etiologic implications. Cancer 1968;22:234-8
156. Sylvester PE. The hippocampus in Down's syndrome. J. Ment. Defic. Res. 1983;27:227-36
157. Tan YH, Schneider EL, Tischfield J, Epstein CJ, Ruddle FH. Human chromosome 21 dosage: effect on the expression of the interferon induced antiviral state. Science 1974;186:61-3
158. Tanaka M, Ohashi R, Nakamura R, Shinmura K, Kamo T, Sakai R, Sugimura H. Tiam1 mediates neurite outgrowth induced by ephrin-B1 and EphA2. EMBO J. 2004;23:1075-88
159. Tatafiore E. Ricerche anatomo-patologiche sull'encefalo e sulle ghiandole a secrezione interna di due lattanti mongoli. Folia Medica 1937;22:1209-36
160. Thiele CJ. Neuroblastoma. In: Masters JRW and Palsson B (Eds). Human cell culture, vol 1. Dordrecht, Great Britain. Kluwer Academic Publishers; 1999;pp21-53
161. Thomas S, Thiery E, Aflalo R, Vayssettes C, Verney C, Berthuy I, Creau N. PCP4 is highly expressed in ectoderm and particularly in neuroectoderm derivatives during mouse embryogenesis. Gene Expr. Patterns 2003;3:93-7
162. Tirode F, Laud-Duval K, Prieur A, Delorme B, Chaarbord P, Delattre O. Les cellules souches mésenchymateuses sont à l'origine des tumeurs d'Ewing. Bull. Cancer 2006; 93:554
163. Tlsty TD, Hein PW. Know thy neighbor: stromal cells can contribute oncogenic signals. Curr. Opin. Genet. Dev. 2001;11:54-9
164. Trebo M, Klaassen R, Weitzman S. Brief report: Neuroblastoma in Down syndrome. Med. Pediatr. Oncol. 1999; 33:125
165. Turkel SB, Itabashi HH. The natural history of neuroblastic cells in the fetal adrenal gland. Am. J. Pathol. 1974;76:225-44
166. Utal AK, Stopka AL, Roy M, Coleman PD. PEP-19 immunohistochemistry defines the basal ganglia and associated structures in the adult human brain, and is dramatically reduced in Huntington's disease. Neuroscience1998; 86:1055-63
167. von Kaisenberg CS, Krenn V, Ludwig M, Nicolaides KH, Brand-Saberi B. Morphological classification of nuchal skin in human fetuses with trisomy 21, 18, and 13 at 12-18 weeks and in a trisomy 16 mouse. Anat. Embryol. 1998; 197:105-24
168. Winningham-Major F, Staecker JL, Barger SW, Coats S, Van Eldik LJ. Neurite extension and neuronal survival activities of recombinant S100 beta proteins that differ in the content and position of cysteine residues. J. Cell Biol. 1989;109:3063-71
169. Wolvetang EJ, Bradfield OM, Hatzistavrou T, Crack PJ, Busciglio J, Kola I, Hertzog PJ. Overexpression of the chromosome 21 transcription factor Ets2 induces neuronal apoptosis. Neurobiol. Dis. 2003;14:349-56
170. Yang Q, Rasmussen SA, Friedman JM. Mortality associated with Down's syndrome in the USA from 1983 to 1997: a population-based study. Lancet 2002; 359:1019-25
171. Yoshida Y, Matsuda S, Ikematsu N, Kawamura-Tsuzuku J, Inazawa J, Umemori H, Yamamoto T. ANA, a novel member of Tob/BTG1 family, is expressed in the ventricular zone of the developing central nervous system. Oncogene1998; 16:2687-93
172. Zheng H, Koo EH. The amyloid precursor protein: beyond amyloid. Mol. Neurodegener. 2006;1:5
173. Zimmer DB, Cornwall EH, Landar A, Song W. The S100 protein family: history, function, and expression. Brain Res. Bull. 1995;37:417-29
174. Zorick TS, Mustacchi Z, Bando SY, Zatz M, Moreira-Filho CA, Olsen B, Passos-Bueno MR. High serum endostatin levels in Down syndrome: implications for improved treatment and prevention of solid tumours. Eur. J. Hum. Genet. 2001;9:811-4